Zoetis Inc. (NYSE:ZTS) Holdings Lifted by XXEC Inc.

XXEC Inc. increased its stake in Zoetis Inc. (NYSE:ZTS) by 30.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,417 shares of the company’s stock after acquiring an additional 5,000 shares during the period. Zoetis makes up approximately 2.7% of XXEC Inc.’s investment portfolio, making the stock its 18th biggest position. XXEC Inc.’s holdings in Zoetis were worth $3,624,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in ZTS. Lake Street Financial LLC boosted its holdings in shares of Zoetis by 11.6% in the third quarter. Lake Street Financial LLC now owns 2,540 shares of the company’s stock valued at $442,000 after acquiring an additional 265 shares in the last quarter. My Legacy Advisors LLC lifted its stake in Zoetis by 2.6% during the third quarter. My Legacy Advisors LLC now owns 4,594 shares of the company’s stock valued at $772,000 after purchasing an additional 115 shares during the last quarter. Townsend Asset Management Corp NC ADV lifted its stake in Zoetis by 0.3% during the third quarter. Townsend Asset Management Corp NC ADV now owns 22,585 shares of the company’s stock valued at $3,929,000 after purchasing an additional 66 shares during the last quarter. AMI Asset Management Corp lifted its stake in Zoetis by 1.1% during the third quarter. AMI Asset Management Corp now owns 355,624 shares of the company’s stock valued at $61,871,000 after purchasing an additional 3,821 shares during the last quarter. Finally, Brookstone Capital Management lifted its stake in Zoetis by 144.1% during the third quarter. Brookstone Capital Management now owns 13,030 shares of the company’s stock valued at $2,190,000 after purchasing an additional 7,692 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 363 shares of the stock in a transaction on Monday, February 12th. The shares were sold at an average price of $197.74, for a total transaction of $71,779.62. Following the transaction, the executive vice president now owns 20,417 shares in the company, valued at approximately $4,037,257.58. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold a total of 2,209 shares of company stock worth $371,293 in the last 90 days. 0.16% of the stock is owned by insiders.

Zoetis Stock Down 0.3 %

ZTS stock traded down $0.53 during midday trading on Tuesday, reaching $159.17. The company had a trading volume of 3,647,859 shares, compared to its average volume of 3,147,432. The company has a 50 day moving average of $170.66 and a two-hundred day moving average of $179.12. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $201.92. The company has a market capitalization of $72.80 billion, a P/E ratio of 31.39, a PEG ratio of 2.42 and a beta of 0.85. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The business had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.19 billion. During the same quarter last year, the company earned $1.15 EPS. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. On average, equities research analysts expect that Zoetis Inc. will post 5.79 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be paid a dividend of $0.432 per share. The ex-dividend date is Thursday, April 18th. This represents a $1.73 annualized dividend and a dividend yield of 1.09%. Zoetis’s dividend payout ratio (DPR) is 34.12%.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ZTS. Piper Sandler reissued an “overweight” rating and set a $195.00 target price (down from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Stifel Nicolaus cut their target price on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday. StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. The Goldman Sachs Group increased their target price on shares of Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. Finally, Barclays cut their target price on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research note on Tuesday, April 23rd. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $216.13.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.